Literature DB >> 8568526

The Functional Limitations Profile may be a valid, reliable and sensitive measure of disability in multiple sclerosis.

J Hutchinson1, M Hutchinson.   

Abstract

This pilot study was designed to evaluate the usefulness of the Functional Limitations Profile (FLP), a validated interval measure of self-report of disability, in studies of multiple sclerosis (MS). It is compared with the standard measure of disability in MS, the Kurtzke Expanded Disability Status Scale (EDSS), and the Illness Severity Score (ISS), which is an interval score derived from the EDSS. Inherent problems of all measures are discussed. On two occasions separated by 6 months, 50 MS patients were assessed prospectively by a neurologist and a psychologist, using the above measures. Validity was reflected in correlation and in agreement between measures. The FLP Physical dimension correlated significantly with the EDSS for both visits (at visit 1: r = 0.77; at visit 2: r = 0.77). Agreement between the interval measures, FLP and ISS, was satisfactory (mean difference +0.18, SD 6.8). The reliability of FLP was assessed by comparing FLP Physical dimension scores in the 30 patients who had not changed clinically between visits (EDSS change < 1.0, ISS change < 3.8). For this unchanged group the mean difference was +0.56 (SD 6.2); the 95% confidence interval (CI) was -2.87 to +1.75. For sensitivity of the FLP the 20 MS patients who had clinically changed between visits were assessed (EDSS =/> 1.0, ISS =/> 3.8). For this changed group the mean difference was -8.0 (SD 9.21); 95% CI was -12.3 to -3.69. The FLP Physical dimension in this pilot study seems to be a valid, reliable and sensitive measure of MS disability. If confirmed by larger studies it would be useful in prospective clinical studies of treatments for MS.

Entities:  

Mesh:

Year:  1995        PMID: 8568526     DOI: 10.1007/bf00866915

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  21 in total

1.  On the evaluation of disability in multiple sclerosis.

Authors:  J F KURTZKE
Journal:  Neurology       Date:  1961-08       Impact factor: 9.910

2.  The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials.

Authors:  B G Weinshenker; G P Rice; J H Noseworthy; W Carriere; J Baskerville; G C Ebers
Journal:  Brain       Date:  1991-04       Impact factor: 13.501

3.  Recognising disability.

Authors: 
Journal:  Lancet       Date:  1991-07-20       Impact factor: 79.321

4.  Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group.

Authors:  J H Noseworthy; M K Vandervoort; C J Wong; G C Ebers
Journal:  Neurology       Date:  1990-06       Impact factor: 9.910

5.  Interrater reliability in assessing functional systems and disability on the Kurtzke scale in multiple sclerosis.

Authors:  M P Amato; L Fratiglioni; C Groppi; G Siracusa; L Amaducci
Journal:  Arch Neurol       Date:  1988-07

6.  The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability.

Authors:  B G Weinshenker; B Bass; G P Rice; J Noseworthy; W Carriere; J Baskerville; G C Ebers
Journal:  Brain       Date:  1989-02       Impact factor: 13.501

7.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

8.  Evaluating self-care activities: comparison of a self-reported questionnaire with an occupational therapist interview.

Authors:  J S Spiegel; M S Hirshfield; T M Spiegel
Journal:  Br J Rheumatol       Date:  1985-11

9.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.

Authors: 
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

10.  Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests.

Authors:  D E Goodkin; D Hertsgaard; J Seminary
Journal:  Arch Phys Med Rehabil       Date:  1988-10       Impact factor: 3.966

View more
  4 in total

1.  Impairment, disability, and handicap in multiple sclerosis. A cross-sectional study in an incident cohort in Møre and Romsdal County, Norway.

Authors:  R Midgard; T Riise; H Nyland
Journal:  J Neurol       Date:  1996-04       Impact factor: 4.849

2.  Effectiveness of a programme of exercise on physical function in survivors of critical illness following discharge from the ICU: study protocol for a randomised controlled trial (REVIVE).

Authors:  Brenda O'Neill; Kathryn McDowell; Judy Bradley; Bronagh Blackwood; Brian Mullan; Gavin Lavery; Ashley Agus; Sally Murphy; Evie Gardner; Daniel F McAuley
Journal:  Trials       Date:  2014-04-27       Impact factor: 2.279

3.  Interferon β-1a subcutaneously 3 times/week clinical outcome in relapsing multiple sclerosis in Finland.

Authors:  Elina Järvinen; Annukka Murtonen; Melina Tervomaa; Marja-Liisa Sumelahti
Journal:  Neurol Int       Date:  2019-11-29

Review 4.  Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis.

Authors:  Sandra Meyer-Moock; You-Shan Feng; Mathias Maeurer; Franz-Werner Dippel; Thomas Kohlmann
Journal:  BMC Neurol       Date:  2014-03-25       Impact factor: 2.474

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.